A Development Study to Evaluate a Full-Face Mask for the Treatment of Obstructive Sleep Apnea
Primary Purpose
Obstructive Sleep Apnea
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
F&P Toffee mask
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea
Eligibility Criteria
Inclusion Criteria:
- AHI ≥ 5 from the diagnostic night
- Aged 22 and over (FDA defined as default)
- Either prescribed APAP, CPAP or Bi-level PAP for OSA
- Existing Full-Face mask user
- Fluent in spoken and written English
Exclusion Criteria:
- Inability to give informed consent
- Participant intolerant to PAP
- Anatomical or physiological conditions making PAP therapy inappropriate
- Current diagnosis of respiratory disease or CO2 retention
- Pregnant or think they may be pregnant
Sites / Locations
- California Sleep Solutions
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
F&P Toffee mask
Arm Description
Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
Outcomes
Primary Outcome Measures
Trial Mask Comfort
Comfort comparison of trial mask compared to their usual mask. Determined from custom questionnaires - Subjective
Trial Mask Performance - Objective
Performance data recorded from the PAP device comparing leak at baseline compared to with trial mask - Objective
Trial Mask Performance - Subjective
Seal leak in comparison to their usual mask. Determine from questionnaires - Subjective
Trial Mask Usability
Whether the patient got the correct orientation and positioning of mask without help. Usability interview - Subjective
Trial Mask Ease-of-Use
Usability of trial mask compared to usual mask. Determined from questionnaires - Subjective
Secondary Outcome Measures
Mask Leak Data
Leak data recorded from PAP device - Objective
Seal Size Determination
Did the sizing tool designed for the trial mask correctly predict which size was best suited for the participant.
Efficacy Data
AHI data recorded from PAP device comparing trial mask use to baseline measurements - Objective
Full Information
NCT ID
NCT03272763
First Posted
August 30, 2017
Last Updated
May 25, 2022
Sponsor
Fisher and Paykel Healthcare
1. Study Identification
Unique Protocol Identification Number
NCT03272763
Brief Title
A Development Study to Evaluate a Full-Face Mask for the Treatment of Obstructive Sleep Apnea
Official Title
A Development Study to Evaluate a Full-Face Mask for the Treatment of Obstructive Sleep Apnea
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 9, 2017 (Actual)
Primary Completion Date
October 29, 2017 (Actual)
Study Completion Date
October 9, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fisher and Paykel Healthcare
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of Obstructive Sleep Apnea (OSA) in the home environment.
Detailed Description
This investigation is a prospective, non-randomized, non-blinded study. Up to 45 OSA participants who currently use a full-face mask will be recruited.
This study will involve a baseline (Visit One) data gathering with the participant's positive airway pressure (PAP) therapy and their usual mask. This will be followed by the participants being fitted with the trial full-face mask for use in-home (Visit Two).
The participant then will come in to return the mask (Visit Three) and give their feedback on their experience using the mask in home in the form of a structured interview during Visit Three. The maximum amount of time the participants will be exposed to the trial mask in-home will be 14 ± 5 days from Visit Two.
The mask and CPAP (if used from the research pool) will be returned to the institution at the conclusion of the trial and participant will return to their usual mask and therapy device for the treatment of their Obstructive Sleep Apnea.
Neither the investigators nor the participants will be blinded to the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
After a period of baseline, all enrolled participants will be put on the same trial mask.
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Actual)
8. Arms, Groups, and Interventions
Arm Title
F&P Toffee mask
Arm Type
Experimental
Arm Description
Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
Intervention Type
Device
Intervention Name(s)
F&P Toffee mask
Intervention Description
Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
Primary Outcome Measure Information:
Title
Trial Mask Comfort
Description
Comfort comparison of trial mask compared to their usual mask. Determined from custom questionnaires - Subjective
Time Frame
14 ± 5 days In-Home
Title
Trial Mask Performance - Objective
Description
Performance data recorded from the PAP device comparing leak at baseline compared to with trial mask - Objective
Time Frame
14 ± 5 days In-Home
Title
Trial Mask Performance - Subjective
Description
Seal leak in comparison to their usual mask. Determine from questionnaires - Subjective
Time Frame
14 ± 5 days In-Home
Title
Trial Mask Usability
Description
Whether the patient got the correct orientation and positioning of mask without help. Usability interview - Subjective
Time Frame
During Visit Two - 20 minutes
Title
Trial Mask Ease-of-Use
Description
Usability of trial mask compared to usual mask. Determined from questionnaires - Subjective
Time Frame
14 ± 5 days In-Home
Secondary Outcome Measure Information:
Title
Mask Leak Data
Description
Leak data recorded from PAP device - Objective
Time Frame
14 ± 5 days In-Home
Title
Seal Size Determination
Description
Did the sizing tool designed for the trial mask correctly predict which size was best suited for the participant.
Time Frame
1 day-time appointment (1 hour) during Visit Two
Title
Efficacy Data
Description
AHI data recorded from PAP device comparing trial mask use to baseline measurements - Objective
Time Frame
14 ± 5 days In-Home
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
AHI ≥ 5 from the diagnostic night
Aged 22 and over (FDA defined as default)
Either prescribed APAP, CPAP or Bi-level PAP for OSA
Existing Full-Face mask user
Fluent in spoken and written English
Exclusion Criteria:
Inability to give informed consent
Participant intolerant to PAP
Anatomical or physiological conditions making PAP therapy inappropriate
Current diagnosis of respiratory disease or CO2 retention
Pregnant or think they may be pregnant
Facility Information:
Facility Name
California Sleep Solutions
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data will not be available to other researchers or institutions. Identifiable participant data will not leave the site and all other data will be de-identified.
Learn more about this trial
A Development Study to Evaluate a Full-Face Mask for the Treatment of Obstructive Sleep Apnea
We'll reach out to this number within 24 hrs